Court blocks mail delivery of abortion pill mifepristone, raising access questions

A federal court blocked the mailing of the abortion pill mifepristone, a move that limits telemedicine and mail-based access to the medication and adds new uncertainty to how patients can obtain it. The ruling comes amid ongoing legal challenges and regulatory scrutiny surrounding abortion drugs, with the FDA’s role and potential appeals likely to shape what happens next for patients and providers.